Curious Retention Agreements at Ligand (LGND)

Daniel Loeb of Third Point Management often provides entertaining copy in his attachments to Third Point’s public filings. Take for example, his letter to the CEO of Ligand Pharmaceuticals (LGND.PK) last fall when he filed a 13D. Loeb quoted one analyst as saying that the CEO was “the worst CEO in biotech